The CALYM* Carnot Institute brings together 13 research teams specialized in lymphoma, most frequent blood cancer. Its objective is to accelerate innovation and its transfer in the lymphoma field through a reinforced public-private partnership and a unique R&D offer from identification of new cellular targets to international phase III registration trials.
LYSA, The Lymphoma Study Association, is a world-renowned cooperative group. LYSARC, The Lymphoma Academic Research Organisation, is Europe’s leading clinical research operations academic organization.
LYSA and LYSARC are together accredited «French cooperative intergroup of international dimension in the field of cancer» by the French National Cancer Institute.
The Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute) – is an international brain and spinal cord research center whose innovative concept and structure make it the only institute of its kind in the world.
The ICM brings patients, doctors and researchers together with the aim of rapidly develop treatments for disorders of the nervous system and enable patients to benefit from them as quickly as possible.
The best scientists from all backgrounds and countries come together at the Institute to perform leading-edge research in this area. To help researchers advance in their work and give patients tangible reasons for hope, we must all play a role: government agencies, corporate actors and individuals. No one can afford to idly stand by, because this fight is vital to every one of us.
The Institut Curie is a Comprehensive Cancer Centre located in the Paris area (France) that brings together a Research Centre (staff of 1 000 +) and a Hospital (staff of 2 000 +). The Institut Curie is active in various topics (Biology, Physics, Chemistry and Medicine) which enrich our understanding of the complexity of Cancer and has been able to create conditions that foster collaborations.
The main and unique asset of the Institut Curie lies in the proximity existing between principal investigators conducting early phases clinical trials, and researchers directing basic or translational research programs with the objective of transposing discoveries as quickly as possible so as to improve diagnostic, prognostic, and therapeutic tools.
What Institut Curie has to offer to industrial partners is tailor-made collaborative research projects based on the internal expertise of our teams as well as our advanced technical platforms.
The Institut Pasteur, a private foundation with officially recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research with a network of 33 institutes worldwide. In the pursuit of its mission to prevent and fight against diseases in France and throughout the world, the Institut Pasteur operates in four main areas: scientific and medical research, public health and health monitoring, teaching, and business development and technology transfer.
More than 2,400 people work on its Paris campus. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology. Its 130 units also focus their research on certain cancers, genetic and neurodegenerative diseases, genomics and developmental biology. This research aims to expand our knowledge of living organisms in a bid to lay the foundation for new prevention strategies and novel therapeutics. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS.
With a portfolio of 350 patent families, 24 new spin-off companies, and over 170 license/sublicense and research agreements in the fields of diagnostics, vaccines and therapeutics, the Institut Pasteur plays a major role in technology transfer activities that directly benefit patients and generate significant resources to further support its research activities.
The Institut de la Vision is one of the most important research centers in Europe on eye diseases. Conceived as a place of gathering and exchanges, it brings together in a single building researchers, clinicians and industrial partners to enable sharing of skills and ideas, and to speed up the translation of fundamental discoveries into new treatments for patients.
The Institute’s goal is to discover, test and develop treatments and technological innovations in order to restore vision, to prevent or limit visual impairment, and to improve the autonomy and quality of life of patients.
The Institut de la Vision functions in synergy with the Quinze-Vingts National Eye Hospital, the Paris-based Ophthalmology Clinical Investigation Center and the National Reference Center for Retinal Dystrophies. It harbors, aside from the integrated research center an incubator for innovative start-ups.
The Brain Sciences Foundation (BSF) is a nonprofit 501(c)3 organization committed to increasing awareness, supporting innovative research and improving methods for the diagnosis and treatment of various neurological conditions. BSF is a multifaceted organization drawing together fellows from a wide range of scientific disciplines, providing extensive knowledge of neuronal processes, degeneration and psychological expression at all stages. Recent research initiatives focus on the development of brain and neuron interfacing.
The Centre Henri Becquerel is a comprehensive cancer center located in Rouen, France, belonging to the Unicancer group of French comprehensive cancer centers. It was created in 1960, and named after the French physicist who shared the discovery of radioactivity with Marie and Pierre Curie. It has three missions: patients care, research and teaching. In research it has two main branches: basic research and clinical research. The center has an oncologic genetics laboratory dedicated to the study of genetic changes in tumor tissue and the special causes of tumor development. The Centre Henri Becquerel is also distinguished for its many studies and publications in the field of lymphoma, in the framework of the LYSA group (a component of the CALYM Carnot institute) activities.
The Center for Neurological Imaging is a joint venture between the Departments of Neurology and Radiology at Brigham and Women's Hospital. It consists of two sections : the Image Analysis Laboratory (IAL), and the Magnetic Resonance Imaging Facility (MRI).
State-of-the-art imaging systems and a powerful computer facility provide outstanding capability for imaging the human central nervous system, and then quantify and visualize CNS structures. Resources are also committed towards the creation of easier ways to manage patient data for doctors.
The Center for Personalized Cancer Therapy (CPCT) is a joint program of the University of Massachusetts Boston and the Dana Farber/Harvard Cancer Center (DF/HCC). A scientific focus of the center will be to elucidate how lifestyle choices, particularly those that promote diet-induced obesity and type 2 diabetes mellitus (‘diabesity’), modulate the tumor microenvironment, and how such modulation affects tumor initiation, progression, and response to therapy.
Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.
The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio—part of The Harrington Project for Discovery & Development—aims to advance medicine and society by enabling our nation’s most inventive physician-scientists to turn their discoveries into medicines that improve human health.
Henri Mondor hospital is a university hospital located in Créteil, France, belonging to the Albert Chenevier - Henri Mondor hospital group. It offers close to 1,000 beds and is operated by 4,000 healthcare professionals, who treat a year around 40,000 patients. It covers the majority of medical and surgical disciplines, to the exception of mother & child care, and offers post-acute and rehabilitation cares. It is a teaching and research center, host of 9 INSERM and 2 CNRS research units, as well as many university and hospital labs
LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups. It offers fully permitted laboratory and office space for as many as 25 startups comprising approximately 100 scientists and entrepreneurs.
The Massachusetts Office of International Trade and Investment (MOITI) is the Commonwealth’s primary international business development agency charged with promoting trade and investment with global partners in Massachusetts and around the world. Their office is dedicated to building successful international collaborations and partnerships essential to bringing new economic opportunities and investments to the Commonwealth. MOITI’s mission is simple: strengthen the Massachusetts economy, create jobs and increase the Commonwealth’s international presence.
The National Emerging Infectious Diseases Laboratories (NEIDL) is part of a national network of secure facilities studying infectious diseases that are—or have the potential to become—major public health concerns. The laboratories are dedicated to the development of diagnostics, vaccines, and treatments to combat emerging and re-emerging infectious diseases. In addition to BSL-2 and BSL-3 laboratories, the NEIDL houses a BSL-4 laboratory. The NEIDL adds to the growing life sciences industry in the region, throughout the Commonwealth of Massachusetts, and across the country.
The Entrepreneurship Center at UCSF provides the knowledge, support and connections needed by our community of scientists and clinicians who want to commercialize their inventions through a startup. They aim to empower their community by providing courses, programs and a network to expose them to the entrepreneurial mindset and the Silicon Valley ecosystem that is the world's standard. They support entrepreneurial interests in all areas of life science/healthcare, whether therapeutics, research tools, medical devices, diagnostics, digital health or Big Data.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Epizyme is a clinical stage biopharmaceutical company that is creating novel epigenetic therapies for cancer patients. We have built a proprietary library of more than 30,000 histone methyl transferase inhibitors and have clinical programs targeting the HMTs EZH2 and DOT1L.
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Their expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help to deliver better care to more patients.
Johnson & Johnson Innovation Centers are home to investment teams that work closely with entrepreneurs to advance products and technology up to proof-of-concept across the pharmaceuticals, medical device & diagnostic and consumer sectors.
Keosys Medical Imaging uses technology and innovation to provide flexible medical imaging solutions for clinical trials and multisite academic studies. Headquartered in France, Keosys has become a European leader in Imaging Data Management Systems with a fully integrated workflow. Keosys also provides advanced medical imaging software that is valuable for 2D and 3D image viewing and analysis.
Pioneer in the development of a new class of drugs made of messenger RNA (mRNA). Moderna's novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas.
Oracle is focused on making high quality healthcare synonymous with cost effective care and believes the sophisticated tools used to expand “Precision Medicine” should be leveraged to make “Population Health” a broad success with the support of modern, agile, business systems. Oracle, and its partners, have embraced this challenge and built the most powerful and flexible tools that enable healthcare providers and payers to embrace new care models, foster change, engage a modern workforce, and create optimized business processes.
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Spark is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist.
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.